Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: A matched case-control study

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 5, 2012, Pages 639-644

  Vila Corcoles, Angel ^a   Ochoa Gondar, Olga ^a   Rodriguez Blanco, Teresa ^b   Gutierrez Perez, Antonia ^a,b   Vila Rovira, Angel ^b  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b Research Institute University Primary Care IDIAP Jordi Gol   (Spain)

Author keywords

Case control; Chronic pulmonary disease; Effectiveness; Pneumococcal pneumonia; Pneumococcal polysaccharide vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTEREMIC STREPTOCOCCUS PNEUMONIA; BLOOD CULTURE; CHRONIC LUNG DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG EFFICACY; FATALITY; FEMALE; HIGH RISK POPULATION; HOSPITAL PATIENT; HUMAN; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; NONBACTEREMIC STREPTOCOCCUS PNEUMONIA; OBSERVATIONAL STUDY; OUTPATIENT; POPULATION BASED CASE CONTROL STUDY; RISK REDUCTION; SEROTYPE; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIA; URINARY ANTIGEN TEST; VACCINATION;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; TREATMENT OUTCOME;

EID: 84863673293     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19466     Document Type: Article

References (26)

1. Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005; 26:563-74; PMID: 16388428; DOI: 10.1055/s-2005-925523.
2. Torres A, Dorca J, Zalacaín R, Bello S, El-Ebiary M, Molinos L, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 1996; 154:1456-61; PMID: 8912764.
3. BTS Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52:S7-15.
4. COPD: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59:181-272; PMID: 14985544.
5. GOLD Executive Committee. Global strategy for diagnosis, management, and prevention of COPD [updated 2008]. Available from: http://www.goldcopd.com/ 2008.
6. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154:2666-77; PMID: 7993150; DOI: 10.1001/archinte.1994.00420230051007.
7. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004; 19:353-63; PMID: 15180106; DOI: 10.1023/B:EJEP.0000024701. 94769.98.
8. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; :CD000422; PMID: 18253977.
9. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48-58; PMID: 19124790; DOI: 10.1503/cmaj.080734.
10. Walters JA, Smith S, Poole PJ, Granger RH, Wood-Baker R, Cates CJ, et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; 11:CD001390; PMID: 21069668.
11. Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; 11:CD001390; PMID: 21069668.
12. Gutiérrez F, Masiá M, Rodríguez JC, Ayelo A, Soldán B, Cebrián L, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36:286-92; PMID: 12539069; DOI: 10.1086/345852.
13. Rosón B, Fernández-Sabé N, Carratalà J, Verdaguer R, Dorca J, Manresa F, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004; 38:222-6; PMID: 14699454; DOI: 10.1086/380639.
14. Alfageme I, Vazquez R, Reyes N, Muñoz J, Fernández A, Hernandez M, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61:189-95; PMID: 16227328; DOI: 10.1136/thx.2005.043323.
15. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999; 159:2437-42; PMID: 10665892; DOI: 10.1001/archinte.159.20.2437.
16. Franzen D. Clinical efficacy of pneumococcal vaccination - a prospective study in patients with longstanding emphysema and/or bronchitis. Eur J Med Res 2000; 5:537-40; PMID: 11147998.
17. Ochoa-Gondar O, Vila-Corcoles A, Ansa X, Rodriguez-Blanco T, Salsench E, de Diego C, et al. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. Vaccine 2008; 26:1955-62; PMID: 18343541; DOI: 10.1016/j.vaccine.2008.02.021.
18. Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J Gen Intern Med 2007; 22:62-7; PMID: 17351841; DOI: 10.1007/s11606-007-0118-3.
19. Sumitani M, Tochino Y, Kamimori T, Fujiwara H, Fujikawa T. Additive inoculation of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients. Intern Med 2008; 47:1189-97; PMID: 18591839; DOI: 10.2169/internalmedicine.47.0799.
20. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102-6; PMID: 20814406.
21. Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean AM, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278:1333-9; PMID: 9343464; DOI: 10.1001/jama.1997. 03550160053038.
22. Evers SM, Ament AJ, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007; 26:531-40; PMID: 17570001; DOI: 10.1007/s10096-007-0327-z.
23. Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, et al. Rationale and design of CAPITA: a RCT of 13- valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378-83; PMID: 18990781.
24. Vila-Córcoles A, Ochoa-Gondar O, Ester F, Sarrá N, Ansa X, Saún N. Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up. BMC Public Health 2006; 6:231; PMID: 16981982; DOI: 10.1186/1471-2458-6-231.
25. Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, et al. Clinical effectiveness of 23- valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 2009; 27:1504-10; PMID: 19171174; DOI: 10.1016/j.vaccine.2009.01.013.
26. Hosmer DW, Lemeshow SA. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons, Inc.; 2000. p. 223-259.